GDF15 and Thromboembolism: In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, GDF-15 was shown to be an independent risk factor not only for major bleeding complications but also for mortality and stroke in AF patients randomized to either warfarin or apixaban [14].